News articles about Edge Therapeutics (NASDAQ:EDGE) have trended somewhat positive on Thursday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edge Therapeutics earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.2652774138112 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news headlines that may have effected Accern Sentiment’s analysis:

EDGE has been the subject of a number of recent research reports. BidaskClub raised shares of Edge Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 3rd. Zacks Investment Research raised shares of Edge Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 29th.

Edge Therapeutics (NASDAQ:EDGE) traded down 0.56% during midday trading on Thursday, hitting $10.60. 24,253 shares of the company were exchanged. Edge Therapeutics has a one year low of $7.30 and a one year high of $13.50. The stock’s market capitalization is $327.02 million. The firm’s 50-day moving average price is $10.28 and its 200-day moving average price is $10.09.

Edge Therapeutics (NASDAQ:EDGE) last released its quarterly earnings results on Tuesday, August 1st. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.44). Equities research analysts anticipate that Edge Therapeutics will post ($1.87) earnings per share for the current year.

In other Edge Therapeutics news, insider Albert N. Marchio II sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 29th. The shares were sold at an average price of $10.42, for a total transaction of $26,050.00. Following the completion of the transaction, the insider now owns 3,361 shares in the company, valued at approximately $35,021.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Brian A. Leuthner sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $10.96, for a total transaction of $82,200.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 36,000 shares of company stock valued at $379,315. Company insiders own 36.19% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Edge Therapeutics (EDGE) Share Price” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/10/12/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-edge-therapeutics-edge-share-price.html.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Insider Buying and Selling by Quarter for Edge Therapeutics (NASDAQ:EDGE)

Receive News & Stock Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related stocks with our FREE daily email newsletter.